Physician profile
Davinder Dhillon
NPI 1750933636
$263.91
in general payments reported to CMS, 2019-2025
10 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.30 · 2022: $18.15 · 2024: $41.67 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $54.30 | 2019-2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $41.67 | 2024 | Uzedy |
| Axsome Therapeutics, INC. | $30.20 | 2025 | Auvelity |
| Pfizer INC. | $23.70 | 2025 | |
| Vanda Pharmaceuticals INC. | $22.16 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $20.12 | 2025 | Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $19.56 | 2025 | Zepbound, Mounjaro |
| Supernus Pharmaceuticals, INC. | $18.43 | 2025 | Qelbree |
| Itamar Medical INC | $18.15 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davinder Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.